Previous studies have shown that the EGFR inhibitor erlotinib (TarcevaTM) significantly inhibited cell motility, invasiveness, tumor growth, and spontaneous lung metastasis in EGFR-expressing IBC models[31]. The gene discussed is EGFR; the disease is neoplasm.